Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

Related Articles

Evolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancer.

Clin Obstet Gynecol. 2012 Mar;55(1):131-55

Authors: Seamon LG, Richardson DL, Copeland LJ

Abstract
This chapter reviews some of the sentinel Gynecologic Oncology Group (GOG) ovarian trials, describes their rationale, provides summary tables for reference, and is organized into early ovarian cancer (GOG 1, 7601, 7602, 95, 157, 175, 212), advanced ovarian cancer optimal (2, 25, 52, 104, 114, 158, 172, 182, 178, 212, 252), and suboptimal disease (3, 22, 47, 97, 111, 162, 182, 218, 252, 262).

PMID: 22343234 [PubMed - indexed for MEDLINE]

Paclitaxel hts screening Paclitaxel Nov-Onxol